Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for immunodeficiency.

F Candotti1

  • 1Clinical Gene Therapy Branch, National Human Genome Research Institute, National Institutes of Health, 10 Center Drive, Building 10, Room 10C103, Bethesda, MD 20892-1851, USA. fabio@nhgri.nih.gov

Current Allergy and Asthma Reports
|March 15, 2002
PubMed
Summary

Human gene therapy has advanced significantly since the 1990s, with early successes in treating adenosine deaminase (ADA) deficiency and chronic granulomatous disease (CGD). Recent breakthroughs in X-linked severe combined immunodeficiency (XSCID) highlight gene transfer

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The long terminal repeat negative control region is a critical element for insertional oncogenesis after gene transfer into hematopoietic progenitors with Moloney murine leukemia viral vectors.

Gene therapy·2016
Same author

Activated STING in a vascular and pulmonary syndrome.

The New England journal of medicine·2014
Same author

Development of IgA nephropathy-like glomerulonephritis associated with Wiskott-Aldrich syndrome protein deficiency.

Clinical immunology (Orlando, Fla.)·2011
Same author

Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype.

Scandinavian journal of immunology·2011
Same author

Immunodeficiencies: injecting some safety into SCID gene therapy?

Gene therapy·2008
Same author

Gene therapy for primary immune deficiencies.

Current opinion in allergy and clinical immunology·2002

Area of Science:

  • Immunology and Genetics
  • Gene Therapy Development

Background:

  • Primary immunodeficiency (ID) disorders have been pivotal in advancing human gene therapy since the early 1990s.
  • Adenosine deaminase (ADA) deficiency was the first disease targeted by gene therapy and hematopoietic stem cell gene transfer.

Purpose of the Study:

  • To review the historical development and recent advances in gene therapy for primary immunodeficiencies.
  • To highlight the role of technical progress in gene transfer for clinical success in ID treatment.

Main Methods:

  • Review of historical clinical gene therapy trials for primary immunodeficiencies.
  • Analysis of gene transfer techniques and their impact on therapeutic outcomes.

Main Results:

  • Pioneering gene therapy for ADA deficiency established the foundation for treating inherited immune disorders.

Related Experiment Videos

  • Successful gene transfer in chronic granulomatous disease (CGD) demonstrated therapeutic potential.
  • Recent successful genetic correction in X-linked severe combined immunodeficiency (XSCID) represents a major advancement.

    • Conclusions:

    • Gene therapy has shown significant promise and success in treating various primary immunodeficiencies.
    • Continued technical progress in gene transfer is crucial for expanding gene therapy applications to other ID forms.